IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors

BACKGROUND: High serum interleukin (IL-6) levels may cause resistance to immunotherapy by modulation of myeloid cells in the tumor microenvironment. IL-6 signaling blockade is tested in cancer, but as this inflammatory cytokine has pleiotropic effects, this treatment is not always effective. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Beyranvand Nejad, Elham, Labrie, Camilla, van Elsas, Marit J, Kleinovink, Jan Willem, Mittrücker, Hans-Willi, Franken, Kees L M C, Heink, Sylvia, Korn, Thomas, Arens, Ramon, van Hall, Thorbald, van der Burg, Sjoerd H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061866/
https://www.ncbi.nlm.nih.gov/pubmed/33879600
http://dx.doi.org/10.1136/jitc-2021-002460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061866/
https://www.ncbi.nlm.nih.gov/pubmed/33879600
http://dx.doi.org/10.1136/jitc-2021-002460

Ejemplares similares